文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

生物标志物预测医院获得性急性肾损伤的比较准确性:系统评价与荟萃分析

Comparative accuracy of biomarkers for the prediction of hospital-acquired acute kidney injury: a systematic review and meta-analysis.
PubMed 文献 · Crit Care · 2022-11-12
一句话结论含NGAL的生物标志物对医院获得性AKI预测准确性最佳,尤其内科患者;危重症患者中各标志物预测性能相似。

该研究检索PubMed、Medline、Embase和Cochrane Library截至2022年8月15日的文献,纳入110项研究共38725例成人患者,比较NGAL、KIM-1、L-FABP、IL-18及TIMP-2×IGFBP-7预测AKI的性能。尿NGAL/肌酐(DOR 16.2,95%CI 10.1-25.9)、尿NGAL(DOR 13.8,95%CI 10.2-18.8)和血NGAL(DOR 12.6,95%CI 9.3-17.3)诊断准确性最佳。亚组分析显示非危重症患者中NGAL类优于尿IL-18,危重症患者中各标志物准确性相似;内科及非脓毒症患者尿NGAL优于尿IL-18、尿L-FABP和尿TIMP-2×IGFBP-7;外科患者尿NGAL/肌酐和尿KIM-1准确性最佳。HSROC值尿NGAL/肌酐91.4%、尿NGAL 85.2%、血NGAL 84.7%。

要点

  • 尿NGAL/肌酐(DOR 16.2,95%CI 10.1-25.9)、尿NGAL(DOR 13.8,95%CI 10.2-18.8)、血NGAL(DOR 12.6,95%CI 9.3-17.3)对AKI预测准确性最佳。
  • 危重症患者中所有生物标志物诊断准确性相似,NGAL类优势不明显。
  • 内科及非脓毒症患者中尿NGAL预测性能优于尿IL-18、尿L-FABP和尿TIMP-2×IGFBP-7。
  • 外科患者中尿NGAL/肌酐和尿KIM-1诊断准确性最佳。
  • HSROC值:尿NGAL/肌酐91.4%、尿NGAL 85.2%、血NGAL 84.7%。

适用人群与场景

  • 成人(>18岁)患者,研究场景包括内科、外科、危重症及非危重症患者,用于预测医院获得性急性肾损伤(AKI)的发生。

研究设计与关键结果

  • 系统评价与荟萃分析,检索PubMed、Medline、Embase和Cochrane Library截至2022年8月15日,从1803篇摘要中筛选出242篇相关研究,最终纳入110项研究共38725例患者。
  • 尿NGAL/肌酐诊断比值比(DOR)16.2(95%CI 10.1-25.9),尿NGAL DOR 13.8(95%CI 10.2-18.8),血NGAL DOR 12.6(95%CI 9.3-17.3),为预测AKI风险诊断准确性最佳的标志物。
  • 亚组分析:非危重症患者中,尿NGAL、尿NGAL/肌酐和血NGAL对AKI的诊断准确性优于尿IL-18;危重症患者中所有生物标志物诊断准确性相似。
  • 内科及非脓毒症患者中,尿NGAL预测性能优于尿IL-18、尿L-FABP和尿TIMP-2×IGFBP-7。
  • 外科患者中,尿NGAL/肌酐和尿KIM-1诊断准确性最佳。
  • HSROC值:尿NGAL/肌酐91.4%,尿NGAL 85.2%,血NGAL 84.7%。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,采用GRADE标准评价证据质量。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在内科及非脓毒症患者中,可考虑使用尿NGAL预测医院获得性AKI的发生。
  • 在外科患者中,尿NGAL/肌酐可能是最准确的预测标志物。
  • 在危重症患者中,各种生物标志物预测性能相似,选择时需结合临床情况。

指南或共识出处

  • 系统评价与荟萃分析,注册号CRD42020207883,注册日期2020年10月06日。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Several biomarkers have been proposed to predict the occurrence of acute kidney injury (AKI); however, their efficacy varies between different trials. The aim of this study was to compare the predictive performance of different candidate biomarkers for AKI.

METHODS: In this systematic review, we searched PubMed, Medline, Embase, and the Cochrane Library for papers published up to August 15, 2022. We selected all studies of adults (> 18 years) that reported the predictive performance of damage biomarkers (neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty acid-binding protein (L-FABP)), inflammatory biomarker (interleukin-18 (IL-18)), and stress biomarker (tissue inhibitor of metalloproteinases-2 × insulin-like growth factor-binding protein-7 (TIMP-2 × IGFBP-7)) for the occurrence of AKI. We performed pairwise meta-analyses to calculate odds ratios (ORs) and 95% confidence intervals (CIs) individually. Hierarchical summary receiver operating characteristic curves (HSROCs) were used to summarize the pooled test performance, and the Grading of Recommendations, Assessment, Development and Evaluations criteria were used to appraise the quality of evidence.

RESULTS: We identified 242 published relevant studies from 1,803 screened abstracts, of which 110 studies with 38,725 patients were included in this meta-analysis. Urinary NGAL/creatinine (diagnostic odds ratio [DOR] 16.2, 95% CI 10.1-25.9), urinary NGAL (DOR 13.8, 95% CI 10.2-18.8), and serum NGAL (DOR 12.6, 95% CI 9.3-17.3) had the best diagnostic accuracy for the risk of AKI. In subgroup analyses, urinary NGAL, urinary NGAL/creatinine, and serum NGAL had better diagnostic accuracy for AKI than urinary IL-18 in non-critically ill patients. However, all of the biomarkers had similar diagnostic accuracy in critically ill patients. In the setting of medical and non-sepsis patients, urinary NGAL had better predictive performance than urinary IL-18, urinary L-FABP, and urinary TIMP-2 × IGFBP-7: 0.3. In the surgical patients, urinary NGAL/creatinine and urinary KIM-1 had the best diagnostic accuracy. The HSROC values of urinary NGAL/creatinine, urinary NGAL, and serum NGAL were 91.4%, 85.2%, and 84.7%, respectively.

CONCLUSIONS: Biomarkers containing NGAL had the best predictive accuracy for the occurrence of AKI, regardless of whether or not the values were adjusted by urinary creatinine, and especially in medically treated patients. However, the predictive performance of urinary NGAL was limited in surgical patients, and urinary NGAL/creatinine seemed to be the most accurate biomarkers in these patients. All of the biomarkers had similar predictive performance in critically ill patients. Trial registration CRD42020207883 , October 06, 2020.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Pan HC, Yang SY, Chiou TT, et al. Comparative accuracy of biomarkers for the prediction of hospital-acquired acute kidney injury: a systematic review and meta-analysis. Crit Care. 2022. PMID: 36371256. doi:10.1186/s13054-022-04223-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。